Lysosomal Acid Lipase (LAL) Deficiency Registry

Study Identifier:
ALX-LALD-501
ClinicalTrials.gov Identifier:
NCT01633489
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
1-855-752-2356 or [email protected]
Recruiting

Study Details

Medical Condition
  • Unmapped
Study Drug
    Date
    May 2013 - Aug 2029
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    N/A
    Patient Requirements
    Sex: Female & Male
    Age: N/A
    Requirements Information
    Sex
    Female & Male
    Age
    N/A

    Study Details

    Medical Condition
    • Unmapped
    Study Drug
      Date
      May 2013 - Aug 2029
      Phase 1
      Phase 2
      Phase 3
      Phase 4
      N/A
      Patient Requirements
      Sex: Female & Male
      Age: N/A years
      Requirements Information

      Protocol Summary

      This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary.

      Trial Locations

      Location
      Status
      Location
      Clinical Trial Site
      Phoenix, Arizona, United States, 85016
      Status
      Recruiting
      Location
      Clinical Trial Site
      Stanford, California, United States, 94305
      Status
      Recruiting
      Location
      Clinical Trial Site
      Miramar, Florida, United States, 33025
      Status
      Recruiting
      Location
      Clinical Trial Site
      Orlando, Florida, United States, 32806
      Status
      Recruiting
      Location
      Clinical Trial Site
      Atlanta, Georgia, United States, 30322
      Status
      Recruiting
      Location
      Clinical Trial Site
      Chicago, Illinois, United States, 60611
      Status
      Recruiting